¼¼°èÀÇ ¿¥Æø½º Ä¡·á ½ÃÀå
Mpox Therapeutics
»óǰÄÚµå : 1794496
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿¥Æø½º Ä¡·á ½ÃÀåÀº 2030³â±îÁö 1¾ï 3,270¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¿¥Æø½º Ä¡·á ½ÃÀåÀº 2030³â¿¡´Â 1¾ï 3,270¸¸ ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀΠõ¿¬µÎ ¹é½ÅÀº CAGR 5.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 7,550¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×¹ÙÀÌ·¯½ºÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,450¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿¥Æø½º Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 2,450¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 10.3%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 2,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.4%¿Í 6.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿¥Æø½º Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö Ç×¹ÙÀÌ·¯½º Ä¡·á°¡ ¼öµÎ Ä¡·áÀÇ ÇÙ½ÉÀΰ¡?

Ç×¹ÙÀÌ·¯½º Ä¡·á´Â ÁßÁõ Æó·Å ȯÀÚ¸¦ °ü¸®Çϰí ÇÕº´ÁõÀ» ¾ïÁ¦ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â °¨¿°ÀÌ È®ÀÎµÈ ÈÄ ¹ÙÀÌ·¯½ºÀÇ º¹Á¦¸¦ ¾ïÁ¦ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇöÀç »ç¿ë °¡´ÉÇÑ ¿É¼Ç¿¡´Â ¿ø·¡ °ü·Ã ¹ÙÀÌ·¯½º¸¦ À§ÇØ °³¹ßµÈ Ç×¹ÙÀÌ·¯½ºÁ¦°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ Ä¡·áÁ¦¸¦ ÅëÇØ ÀÓ»óÀÇ´Â ¸é¿ª°áÇÌ È¯ÀÚ, ÀÓ»êºÎ, ¼Ò¾Æ µî °íÀ§Ç豺 ȯÀÚ¸¦ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. Ç×¹ÙÀÌ·¯½º Ä¡·á¸¦ ÅëÇÑ Á¶±â °³ÀÔÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÁßÁõÈ­ À§ÇèÀ» °¨¼Ò½Ãŵ´Ï´Ù.

ÀÇ·áÁøÀº ÀÓ»óÀû ÁßÁõµµ¿¡ µû¶ó Ç×¹ÙÀÌ·¯½ºÁ¦ Åõ¿© ½ÃÀÛ°ú ¿ë·®À» °áÁ¤ÇÏ´Â ÇÁ·ÎÅäÄÝ¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Á¤¸ÆÁÖ»ç ¶Ç´Â °æ±¸ ¿ä¹ýÀº ȯÀÚÀÇ »óÅÂ¿Í ¾à¹°ÀÇ °¡¿ë¼º¿¡ µû¶ó ¼±Åõ˴ϴÙ. Ä¡·á¿¡´Â ºÎÀÛ¿ëÀ» ¸ð´ÏÅ͸µÇÏ°í ½ÅÀåÀ̳ª °£ ±â´É¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ´Â °Íµµ ÇÊ¿äÇÕ´Ï´Ù. ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­´Â Ç×¹ÙÀÌ·¯½ºÁ¦ ºñÃà¿¡ ´ëÇÑ Àû½Ã Á¢±Ù°ú ¸íÈ®ÇÑ Ä¡·á ÁöħÀÌ È¿°úÀûÀΠȯÀÚ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù.

¾î¶² »õ·Î¿î Ä¡·á¹ýÀÌ µîÀåÇÏ°í ¿¬±¸µÇ°í Àִ°¡?

MPOXÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÏ°í °øÁߺ¸°Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ ¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ·¯½º º¹Á¦ ¸ÞÄ¿´ÏÁòÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ½ÇÇèÀû ¾à¹°Àº ´Ù¾çÇÑ ÀÓ»ó °³¹ß ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ÀϺΠÈĺ¸ ¾à¹°Àº ´õ ±¤¹üÀ§ÇÑ Ç×¹ÙÀÌ·¯½º Ȱ¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ mpox Àü¿ëÀ¸·Î ¼³°èµÈ °Íµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ·¯½º ÁßÈ­¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ¸ð³ëŬ·Î³Î Ç×ü Æò°¡µµ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¼öµ¿ ¸é¿ªÀ» Á¦°øÇϰí ÁßÁõ ¹× ³­Ä¡¼º ȯÀÚ¸¦ Áö¿øÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇèÀº ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼­ÀÇ ¾ÈÀü¼º, ¿ë·®, À¯È¿¼º Æò°¡¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ƯÈ÷ ¼Ò¾Æ, ³ëÀÎ, ¸é¿ª¾ïÁ¦ÀÚ µî Ãë¾àÇÑ Áý´Ü¿¡ ´ëÇÑ ¾à¹°ÀÇ ¿µÇâÀ» ÀÌÇØÇÏ´Â µ¥ ÁÖÀǸ¦ ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¾à¹° °³¹ßÀÚµéÀº Ä¡·á È¿°ú¸¦ ³ôÀ̱â À§ÇØ Ç×¹ÙÀÌ·¯½ºÁ¦¿Í ¸é¿ªÁ¶ÀýÁ¦¸¦ °áÇÕÇÑ º´¿ë¿ä¹ýµµ ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº Á¤½Ä ½ÂÀÎÀÌ ÁøÇàµÇ´Â µ¿¾È º¸´Ù Æø³ÐÀº Á¢±ÙÀ» Çã¿ëÇϱâ À§ÇØ ÀϺΠġ·á¿¡ ´ëÇØ ±ä±Þ »ç¿ë Çã°¡¸¦ ³»Áֱ⠽ÃÀÛÇß½À´Ï´Ù.

Á¢±Ù°ú À¯ÅëÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

¿¥ÆÅ½º Å×¶óǻƽ½º´Â °øÁß º¸°Ç °æ·Î, ºñ»ó ºñÃà, ±¹Á¦ ¿øÁ¶ ÇÁ·Î±×·¥À» ÅëÇØ ¹èÆ÷µÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ±â°ü, ºñÁ¤ºÎ±â±¸, Á¦Á¶¾÷ü °£ÀÇ ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ÀúÀÚ¿ø Áö¿ª¿¡¼­ÀÇ ÀǾàǰ ºÐ¹è¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Ä¡·á ÇÁ·Î±×·¥¿¡´Â ´ë»ó ȯÀÚ ½Äº°, Ä¡·á ¿ä¹ý °ü¸®, ºÎÀÛ¿ë ¸ð´ÏÅ͸µÀ» À§ÇÑ ÀÓ»óÀÇ¿¡ ´ëÇÑ ±³À°ÀÌ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ Çù·ÂÀû Á¢±Ù ¹æ½ÄÀº ¹ßº´ Áö¿ª¿¡¼­ °øÆòÇÑ Ä¡·á Á¢±Ù¼ºÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

Á¦¾à»çµéÀº ¶ÇÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »ý»ê ´É·ÂÀ» È®´ëÇÏ°í °ø±Þ¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. Çʿ信 µû¶ó »ý»ê·®À» ½Å¼ÓÇÏ°Ô Á¶Á¤ÇÒ ¼ö ÀÖ´Â À¯¿¬ÇÑ Á¦Á¶ °øÁ¤À» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ÇöÀç À¯Åë ½Ã½ºÅÛ¿¡´Â ¿Âµµ Á¦¾î ¿î¼Û, ½Ç½Ã°£ ÃßÀû, ¿ø°ÝÁö±îÁö È¿À²ÀûÀ¸·Î µµ´ÞÇÒ ¼ö ÀÖ´Â Áö¿ª Çãºê µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹°·ù °­È­´Â Àç°í ºÎÁ·À» ¹æÁöÇϰí Àü¿°º´ÀÌ ÀýÁ¤¿¡ ´ÞÇßÀ» ¶§ Ä¡·áÁ¦¸¦ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

¿¥ÆÅ½º Å×¶óǻƽ½º ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

¿¥ÆÅ½º Å×¶óǻƽ½º ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ õ¿¬µÎ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ½Å±Ô Ç×¹ÙÀÌ·¯½ºÁ¦ ±ä±Þ Çã°¡ ¹× ½ÂÀÎÀ¸·Î ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Ãë¾à °èÃþÀ» ´ë»óÀ¸·Î ÇÑ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» Ÿ°ÙÀ¸·Î ÇÑ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ·Î Ä¡·áÀÇ ¼±ÅÃÀÇ ÆøÀ» ³ÐÈú ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶ ´É·ÂÀÇ È®Àå ¹× À¯¿¬ÇÑ °ø±Þ¸ÁÀ» ÅëÇØ ´Ù¾çÇÑ È¯°æ¿¡¼­ÀÇ Á¢±Ù¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ±¹Á¦ ¿øÁ¶ ÇÁ·Î±×·¥ÀÇ È®´ë·Î ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ÀÇ À¯ÅëÀÌ °¡´ÉÇØÁý´Ï´Ù. º´¿ë¿ä¹ý°ú ¸ð³ëŬ·Î³Î Ç×ü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ Ä¡·á Æ÷Æ®Æú¸®¿ÀÀÇ ÆøÀÌ ³Ð¾îÁö°í, ¹Ì·¡ÀÇ Çõ½ÅÀ» Áö¿øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

ºÎ¹®

Ä¡·á(õ¿¬µÎ ¹é½Å, Ç×¹ÙÀÌ·¯½ºÁ¦, ¹é½Ã´Ï¾Æ ¸é¿ª±Û·ÎºÒ¸°); ÃÖÁ¾ »ç¿ë(º´¿ø ÃÖÁ¾ »ç¿ë, Àü¹® Ŭ¸®´Ð ÃÖÁ¾ »ç¿ë, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾ »ç¿ë, ±âŸ ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Mpox Therapeutics Market to Reach US$132.7 Million by 2030

The global market for Mpox Therapeutics estimated at US$90.0 Million in the year 2024, is expected to reach US$132.7 Million by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Smallpox Vaccine, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$75.5 Million by the end of the analysis period. Growth in the Antivirals segment is estimated at 9.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.5 Million While China is Forecast to Grow at 10.3% CAGR

The Mpox Therapeutics market in the U.S. is estimated at US$24.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.2 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Mpox Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antiviral Treatments Central in Mpox Care?

Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.

Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.

What New Treatments Are Emerging or Under Study?

Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.

Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.

How Are Access and Distribution Evolving?

Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.

Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.

Growth in the Mpox Therapeutics Market Is Driven by Several Factors…

Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.

SCOPE OF STUDY:

The report analyzes the Mpox Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â